Fundraising Fox
Moleculin
Houston, US · Founded 2006 · 22 employees on LinkedIn
Find your way into Moleculin
Sign up to see every warm intro you have to Moleculin
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Moleculin team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Moleculin Biotech is a Phase 3 clinical-stage biopharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses, with a lead program (Annamycin) targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma.
Founders & leadership
Moleculin was founded in 2006 by Wally Klemp.
WK
Wally KlempChairman & CEOWally Klemp is Chairman and CEO of Moleculin Biotech, a clinical-stage biopharmaceutical company developing therapeutics for hard-to-treat tumors and viruses. He has prior experience in pharmaceuticals and medical device sectors across drug development, financing, and international business.
DP
Donald PickerExecutive
LH
Lori H BissonAssistant Secretary-Treasurer and AdvisorLori H Bisson is an executive with extensive experience in the life sciences industry, including public company leadership, capital markets transactions, M&A, and board governance. She serves as Executive Officer and Director of Moleculin Biotech, a Phase 3 clinical-stage biopharmaceutical company developing therapeutic candidates for difficult-to-treat tumors and viruses.
Board
MC
Michael ClinardBoard director
RC
Robert ConradBoard director
SD
Stephen DrakeBoard director
JG
J. George GumulkaBoard director
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 1 round · 2014
▶$1.4MraisedOct 2014 · 36 investors · Pharmaceuticals
▶$1.4MraisedOct 2014 · 36 investors · Pharmaceuticals
Officers, directors & promoters on the filing
- Walter V KlempExecutive Officer, Director
- Michael ClinardDirector
- Robert ConradDirector
- Stephen DrakeDirector
- J. George GumulkaDirector
- Donald PickerExecutive Officer, Director
- Lori H BissonExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.4M
- Minimum investment
- $5K
- Finders' fees
- $60K
- First sale
- May 2014
- Incorporated
- Limited Liability Company, Texas
- Federal exemptions
- 05
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Moleculin do?
- Moleculin Biotech is a Phase 3 clinical-stage biopharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses, with a lead program (Annamycin) targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma.
- Who founded Moleculin?
- Moleculin was founded by Wally Klemp in 2006.
- How much funding has Moleculin raised?
- Moleculin has disclosed $1.4M raised across 1 round.
- Where is Moleculin headquartered?
- Moleculin is headquartered in Houston, US.